Medtronic's CRT-D set for approval in mild heart failure patients after FDA panel nod
This article was originally published in Clinica
Executive Summary
An FDA advisory panel has recommended expanding the use of Medtronic's cardiac resynchronisation therapy-defibrillator (CRT-D) to include mildly symptomatic heart failure patients, paving the way for its approval in this population.